Loading...
Dynavax Q1 2025 Earnings Report
Dynavax reported its financial results for the first quarter of 2025, highlighting strong revenue growth and advancements in its vaccine pipeline.
Key Takeaways
Dynavax reported a strong first quarter in 2025, achieving its highest first quarter net product revenue for HEPLISAV-B to date, with total revenues increasing by 34% year-over-year. The company also made significant progress in its pipeline, with key clinical trial milestones for shingles and plague vaccine programs, and new programs in pandemic influenza and Lyme disease entering clinical development.
Record HEPLISAV-B net product revenue of $65.0 million, a 36% increase year-over-year.
Total revenues reached $68.2 million, up 34% from the first quarter of 2024.
HEPLISAV-B's estimated U.S. market share increased to approximately 43%.
New pandemic influenza adjuvant and Lyme disease vaccine programs are planned to enter clinical development in 2025 and 2027, respectively.
Revenue by Segment
Forward Guidance
Dynavax reaffirmed its full year 2025 financial guidance, expecting HEPLISAV-B net product revenue between $305 million and $325 million, and Adjusted EBITDA of at least $75 million.
Positive Outlook
- HEPLISAV-B net product revenue expected to be in the range of $305 million to $325 million for full year 2025.
- Adjusted EBITDA expected to be at least $75 million for full year 2025.
- Anticipates achieving the top half of full year guidance range for HEPLISAV-B revenue.
- Continued advancement of pipeline programs leveraging CpG 1018 adjuvant.
- Focus on disciplined capital allocation and share repurchase program completion.
Challenges Ahead
- No specific negative forward guidance points were explicitly stated in the provided text.
- Potential for market size or actual demand for products to differ from expectations.
- Risks related to the ability to commercialize and supply HEPLISAV-B.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...